Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 19/20 | 0.61 |
| ▸ | PDE4B | Q07343 | 19/20 | 0.61 |
| ▸ | PDE4C | Q08493 | 19/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 19/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21051103 | 1.00 | PDE4A (0.61) | PDE4APDE4BPDE4CPDE4DPOLB | |
| SCHEMBL6829586 | 0.87 | PDE4B (0.54) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7420740 | 0.86 | PDE4A (0.66) | PDE4APDE4BPDE4CPDE4DPOLB | |
| SCHEMBL6129891 | 0.82 | PDE4A (0.73) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6829290 | 0.78 | PDE4A (0.77) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6323001 | 0.78 | PDE4B (0.74) | PDE4APDE4BPDE4CPDE4DPOLB | |
| Bicarbonate SCHEMBL4603657 | 0.78 | PDE4A (0.80) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6322995 | 0.78 | PDE4B (0.74) | PDE4APDE4BPDE4CPDE4DPOLB | |
| SCHEMBL6322447 | 0.78 | PDE4B (0.74) | PDE4APDE4BPDE4CPDE4DPOLB | |
| SCHEMBL6820431 | 0.77 | PDE4B (0.79) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691962-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-10994082-B2 | Inhaler counter | ASTRAZENECA AB (SE) | 2021-05-04 | — | — | US | disclosed |
| US-20190175849-A1 | INHALER COUNTER | BANG & OLUFSEN MEDICOM A/S (DK) | 2019-06-13 | — | — | US | disclosed |
| US-20040171597-A1 | Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha | GLAXO GROUP LIMITED (GB) | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171597-A1 | Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha | NR5A1, HSD17B7, HSD17B1 | PDE4A 1933/4885PDE4B 2371/4885PDE4C 2570/4885 |
| US-11691962-B2 | Therapeutic compounds and compositions | KLK5, KLK2, KLKB1 | PDE4A 584/4885PDE4B 416/4885PDE4C 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.